SPR064, a pro-drug of paclitaxel, has anti-tumorigenic effects in endometrial cancer cell lines and mouse models.
Paclitaxel
SPR064
apoptosis
cell proliferation
endometrial cancer
Journal
American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
02
2020
accepted:
28
05
2020
entrez:
11
9
2020
pubmed:
12
9
2020
medline:
12
9
2020
Statut:
epublish
Résumé
Paclitaxel is one of the most effective and widely used agents in treating a variety of cancers, including endometrial cancer. Because of its poor solubility in water, the current intravenous pharmaceutical paclitaxel is formulated in Cremophor EL and dehydrated in ethanol in equal volumes. Cremophor EL is capable of causing complement activation, which can trigger an immediate hypersensitivity reaction. SPR064 is a pro-drug of paclitaxel which has a much higher solubility as compared to the parent drug; hence, SPR064 can be conveniently formulated in non-cremapor based medium, reducing the risk of cremaphor-related hypersensitivity reactions. The pharmacokinetics and solubility of SPR064 were evaluated in rats. The anti-tumorigenic potential of SPR064 was compared to paclitaxel in endometrial cancer cell lines and a genetically engineered mouse model (
Types de publication
Journal Article
Langues
eng
Pagination
4264-4276Subventions
Organisme : NCI NIH HHS
ID : R37 CA226969
Pays : United States
Informations de copyright
AJTR Copyright © 2020.
Déclaration de conflit d'intérêts
Sundeep Dugar is an employee of Sphaera Pharma Singapore Pte Ltd and Somdutta Sen is an employee of Sphaera Pharma Pvt Ltd. The rest of the authors declare no conflict of interest except that the SPR064 drug was provided to us by Sphaera for these studies.
Références
Obstet Gynecol Clin North Am. 2019 Mar;46(1):89-105
pubmed: 30683268
Cancer Chemother Pharmacol. 2019 Oct;84(4):669-677
pubmed: 31187168
Cell Death Dis. 2014 Jun 12;5:e1291
pubmed: 24922075
Am J Cancer Res. 2019 Oct 01;9(10):2170-2193
pubmed: 31720081
Int J Pharm. 2019 Jun 30;565:219-226
pubmed: 31077761
Oncogene. 2001 Jun 28;20(29):3806-13
pubmed: 11439344
FEBS Lett. 2002 Dec 4;532(1-2):256-60
pubmed: 12459501
Cancer Imaging. 2018 Dec 4;18(1):45
pubmed: 30514387
Recent Results Cancer Res. 2016;208:107-136
pubmed: 27909905
Eur J Cancer. 2010 Jul;46(10):1882-91
pubmed: 20223651
Immunol Allergy Clin North Am. 2017 Nov;37(4):679-693
pubmed: 28965634
Clin Rev Allergy Immunol. 2015 Oct;49(2):177-91
pubmed: 24740483
Cancer Chemother Pharmacol. 2008 Aug;62(3):379-85
pubmed: 17960385
Cancer. 1996 Jan 1;77(1):14-8
pubmed: 8630921
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3896-901
pubmed: 9520464
Mol Biol Cell. 2014 Sep 15;25(18):2677-81
pubmed: 25213191
Cancer Chemother Pharmacol. 2005 Jul;56(1):91-6
pubmed: 15791461
Free Radic Biol Med. 2011 Aug 1;51(3):641-57
pubmed: 21641992
Cancer Lett. 2001 Apr 26;165(2):147-53
pubmed: 11275363
Mol Pharm. 2018 Jun 4;15(6):2484-2488
pubmed: 29762034
Clin Cancer Res. 1998 Dec;4(12):3063-8
pubmed: 9865921
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
BMB Rep. 2016 Jan;49(1):51-6
pubmed: 26246283
Breast Cancer Res Treat. 2012 May;133(1):89-97
pubmed: 21811816
Clin Oncol (R Coll Radiol). 2015 Jan;27(1):40-7
pubmed: 25455846
Cancers (Basel). 2015 Dec 03;7(4):2360-71
pubmed: 26633515
Int J Pharm. 2018 May 5;542(1-2):242-252
pubmed: 29555439
Exp Toxicol Pathol. 2012 May;64(4):357-65
pubmed: 21074392
Gynecol Oncol. 2017 Oct;147(1):30-35
pubmed: 28735629
Chemotherapy. 2011;57(4):298-304
pubmed: 21778718
Nanomedicine (Lond). 2019 May;14(10):1323-1341
pubmed: 31124758
Oncogene. 2004 Mar 15;23(11):2016-27
pubmed: 15021889
Biochem Biophys Res Commun. 2013 Jul 19;437(1):151-5
pubmed: 23806691
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3775-80
pubmed: 10097113
F1000Res. 2017 Jan 27;6:81
pubmed: 28184290
J Natl Cancer Inst. 1998 Feb 18;90(4):300-6
pubmed: 9486816